Industry Insights
-
Building Sustainable Biopharma Supply Chains Starts With Procurement
9/24/2026
Nearly all the industry's emissions happen upstream from core manufacturing functions. This puts sustainability almost entirely on the shoulders of purchasing.
-
Sustainable Facility Design Brings Bayer Instant Savings
9/23/2026
ROI for sustainability initiatives often come later as lower maintenance and utility costs. Bayer's pursuit of LEED certification led to substantial savings up front.
-
In Case You Missed Them: Recapping The FDA's Recent Guidances For Cell And Gene Therapies
9/17/2026
I review 10 of the FDA’s guidances spanning the last 12 months, all of which aid cell and gene therapy companies to assure safety and efficacy of these medicines.
-
Why You Should Measure Comparability Debt Before Ever Starting A Study
9/17/2026
When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down.
-
What FDA Inspectors Want From Your OOS File
9/16/2026
Read enough FDA warning letters and a pattern emerges: Investigators rarely cite a retest that was performed badly. They cite a retest that nobody justified in writing. Let's take a closer look.
-
You Can't CAPA What You Can't Classify
9/16/2026
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
New USP Guidelines, Standards Address Lentivirus Characterization
9/16/2026
The United States Pharmacopeia is rolling out new standards and tools to help manufacturers characterize fragile, complex lentiviral vectors.
-
Inside Kyverna's Autoimmune CAR T Platform Beyond SPS
9/16/2026
Kyverna's progress suggests that autoimmune CAR T's commercial viability will depend as much on manufacturing readiness and focused indication selection as on its potential to deliver durable, drug-free remission.
-
Bringing Next-Gen Sequencing To GMP Scale
9/10/2026
NGS enables broad detection of known and novel viruses in a single assay. Its high sensitivity, specificity, and scalability can meet GMP throughput levels.
-
Risk Managing Through The Void Of ATMP Visible Particle Guidance
9/8/2026
Regulators expect cell therapy manufacturers to prove they control for visible particles, but guidance remains notably quiet on the matter. Companies must get creative or risk clinical holds.